Mundipharma International Limited - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Mundipharma International Limited - Product Pipeline Review - 2014" provides data on the Mundipharma International Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Mundipharma International Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Mundipharma International Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Mundipharma International Limited - Brief Mundipharma International Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mundipharma International Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mundipharma International Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mundipharma International Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mundipharma International Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mundipharma International Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mundipharma International Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mundipharma International Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mundipharma International Limited and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mundipharma International Limited Snapshot 5
Mundipharma International Limited Overview 5
Key Information 5
Key Facts 5
Mundipharma International Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Mundipharma International Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Mundipharma International Limited - Pipeline Products Glance 14
Mundipharma International Limited - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Mundipharma International Limited - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Mundipharma International Limited - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Mundipharma International Limited - Drug Profiles 19
(fluticasone proprionate + formoterol fumarate) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
pralatrexate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
forodesine hydrochloride 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NL-101 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Mundipharma International Limited - Pipeline Analysis 27
Mundipharma International Limited - Pipeline Products by Therapeutic Class 27
Mundipharma International Limited - Pipeline Products by Target 29
Mundipharma International Limited - Pipeline Products by Route of Administration 31
Mundipharma International Limited - Pipeline Products by Molecule Type 32
Mundipharma International Limited - Pipeline Products by Mechanism of Action 33
Mundipharma International Limited - Recent Pipeline Updates 35
Mundipharma International Limited - Dormant Projects 43
Mundipharma International Limited - Company Statement 44
Mundipharma International Limited - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Mundipharma International Limited, Key Information 5
Mundipharma International Limited, Key Facts 5
Mundipharma International Limited - Pipeline by Indication, 2014 8
Mundipharma International Limited - Pipeline by Stage of Development, 2014 9
Mundipharma International Limited - Monotherapy Products in Pipeline, 2014 10
Mundipharma International Limited - Combination Treatment Modalities in Pipeline, 2014 11
Mundipharma International Limited - Partnered Products in Pipeline, 2014 12
Mundipharma International Limited - Partnered Products/ Combination Treatment Modalities, 2014 13
Mundipharma International Limited - Pre-Registration, 2014 14
Mundipharma International Limited - Phase III, 2014 15
Mundipharma International Limited - Phase II, 2014 16
Mundipharma International Limited - Phase I, 2014 17
Mundipharma International Limited - Preclinical, 2014 18
Mundipharma International Limited - Pipeline by Therapeutic Class, 2014 28
Mundipharma International Limited - Pipeline by Target, 2014 30
Mundipharma International Limited - Pipeline by Route of Administration, 2014 31
Mundipharma International Limited - Pipeline by Molecule Type, 2014 32
Mundipharma International Limited - Pipeline Products by Mechanism of Action, 2014 34
Mundipharma International Limited - Recent Pipeline Updates, 2014 35
Mundipharma International Limited - Dormant Developmental Projects,2014 43
Mundipharma International Limited, Other Locations 45
Mundipharma International Limited, Subsidiaries 46